Mizuho's Jared Holz talks what is next for Novo Nordisk

Key Concepts:

• Novo Nordisk's recent performance and CEO ousting
• Market share loss to Eli Lilly in the obesity market
• Potential acquisition strategies for Novo Nordisk
• Business development and R&D options
• PBM partnerships (e.g., CVS deal for Wegovy)
• Challenges in identifying acquisition targets in the biotech sector
• Impact of Chinese biotech development on the global landscape
• M&A activity in the pharmaceutical industry

Novo Nordisk's Challenges and CEO Ousting:

• Novo Nordisk's stock has lost over half its value since its peak in June.
• The company has lost market share in the obesity market to Eli Lilly.
• The ousting of the CEO, Jorgensen, is interpreted as an acknowledgment of missteps and a need for strategic change.
• Despite past outperformance under Jorgensen, recent performance has been subpar.

Potential Strategies for Novo Nordisk:

• Acquisition of Smaller Obesity Players: The company may look to acquire smaller companies to boost its pipeline and spur growth.
• Speeding Up R&D: While possible, this is seen as a slower solution compared to acquisitions.
• PBM Partnerships: The deal with CVS to make Wegovy the preferred drug on some formularies is a positive step, but pricing is a key factor.
• Business Development: The company needs to be more acquisitive. Past acquisitions include Dicerna, Forma, and Catalent manufacturing facilities (for $11 billion to speed up GLP-1 production).
• Diversification: The Street would like to see Novo Nordisk diversify its portfolio.

Challenges in Identifying Acquisition Targets:

• The current landscape is challenging due to the large number of biotech companies (around 800 publicly traded), development at large cap pharma, private companies, and the rise of Chinese biotech.
• It's difficult to ascertain where investors and companies should be looking for assets.
• M&A activity has been more random than usual this year.

M&A Considerations:

• Companies like Novo Nordisk, Merck, and Bristol-Myers need revenue and may be looking for acquisitions.

Notable Quotes:

• "They've been kind of bypassed by Eli Lilly. There have been multiple missteps. So I think at some point they're going to have to regroup."
• "Time is not on their side. I mean, it's late and so is the only hope for them to actually acquire a molecule from somewhere."
• "I don't know. I mean, simply put, I don't know that the this backdrop is probably the most challenging I've ever seen it."

Technical Terms and Concepts:

• GLP-1: Glucagon-like peptide-1, a class of drugs used for diabetes and weight loss.
• PBM: Pharmacy Benefit Manager, a company that manages prescription drug benefits for health insurers and employers.
• Formulary: A list of prescription drugs covered by a health insurance plan.
• M&A: Mergers and Acquisitions.

Synthesis/Conclusion:

Novo Nordisk faces significant challenges due to market share loss and strategic missteps. The ousting of the CEO signals a need for change. The company is likely to pursue acquisitions to boost its pipeline and diversify its portfolio. However, identifying suitable acquisition targets is difficult due to the complex and competitive biotech landscape, including the rise of Chinese biotech. While internal R&D and PBM partnerships are important, acquisitions are seen as a more immediate solution.